基于LASP1/AKT通路探究CXCL12/CXCR4轴调控Th1细胞趋化介导CNP发生的机制

批准号:
82000719
项目类别:
青年科学基金项目
资助金额:
24.0 万元
负责人:
刘祎
依托单位:
学科分类:
前列腺及膀胱良性疾病
结题年份:
2023
批准年份:
2020
项目状态:
已结题
项目参与者:
刘祎
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
慢性非细菌性前列腺炎(CNP)发病率高,治疗后易复发,严重影响患者生活质量,目前机制尚未阐明。研究发现Th1细胞局部浸润可导致CNP发生。前期基于非细菌性前列腺炎动物模型组织测序鉴定并验证出一关键CXCL12/CXCR4轴,其可通过调控淋巴细胞趋化介导CNP发生。文献报道CXCR4蛋白可激活LASP1/AKT通路促进炎症细胞迁移,但具体机制不明。基于预实验结果和文献报道,我们推测“CXCL12/CXCR4轴可通过激活LASP1/AKT信号通路促进Th1细胞迁移至前列腺,引起局部炎症反应,介导CNP发生”。进一步实验拟采用敲低和过表达、抑制剂注射等体内体外实验探究CXCL12/CXCR4轴是通过LASP1/AKT信号通路调控Th1细胞趋化,介导CNP发生;利用免疫共沉淀、蛋白电泳等实验揭示CXCL12/CXCR4轴激活LAPS1/AKT通路的具体作用机制,为CNP的免疫治疗提供新的思路。
英文摘要
Chronic nonbacterial prostatitis (CNP) has a high incidence and is prone to relapse after treatment, which seriously affects the quality of life of patients, but the underlying mechanism has not yet been elucidated. Studies have found that local infiltration of Th1 cells causes the pathogenesis of CNP. In the preliminary studies, we identified and validated a critical CXCL12/CXCR4 axis based RNA-seq analysis of the CNP mouse model, and the axis mediates the pathogenesis of CNP by regulating lymphocyte chemotaxis. Studies reported that CXCR4 regulates the migration of inflammatory cells via activating LASP1/AKT signaling pathway, while the underlying mechanism remains unknown. Based on preliminary results and previous reports, we speculate that “the CXCL12/CXCR4 axis promotes the migration of Th1 cells to the prostate by activating the LASP1/AKT signaling pathway, subsequently, causing local inflammatory responses and mediating the pathogenesis of CNP”. Further experiments are designed to explore how the CXCL12/CXCR4 axis mediates the pathogenesis of CNP via the LASP1/AKT signaling pathway based on knockdown and overexpression, inhibitor injection and other in vivo and in vitro experiments; employing the co-immunoprecipitation, western blot and other experiments to reveal the specific mechanism of how CXCL12/CXCR4 axis activates the LAPS1/AKT pathway. Our study provides a novel inspiration for the immunotherapy of chronic nonbacterial prostatitis patients.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Targeting CXCL12/CXCR4 Signaling with AMD3100 Might Selectively Suppress CXCR4+ T-Cell Chemotaxis Leading to the Alleviation of Chronic Prostatitis.
使用 AMD3100 靶向 CXCL12/CXCR4 信号传导可能会选择性抑制 CXCR4 T 细胞趋化性,从而缓解慢性前列腺炎
DOI:10.2147/jir.s352336
发表时间:2022
期刊:Journal of inflammation research
影响因子:4.5
作者:
通讯作者:
国内基金
海外基金
